ArticleFrontiers in cardiovascular medicine2025
Optimising access: safety and efficacy of venous closure devices in cryoballoon pulmonary vein isolation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Despite technological progress in atrial fibrillation (AF) ablation, vascular access complications remain common. Venous closure systems (VCS) may reduce these events and improve patient comfort, but data on their safety and efficacy following cryoballoon-based pulmonary vein isolation (CB-PVI) are limited. This study assessed acute and long-term outcomes of VCS vs. manual compression and figure-of-eight suture after CB-PVI. Methods: We conducted a prospective, single-centre observational study comparing VCS with figure-of-eight suture plus manual compression post-CB-PVI. VCS patients who underwent CB-PVI between September 2022 and August 2023 were enrolled; controls were a 1:1 age-, sex-, and anticoagulation-matched cohort treated between January 2016 and May 2021. Ultrasound-guided access was used in all VCS cases and routinely from 2018 in controls. Pressure bandage time was ≥60 min in VCS vs. ≥4 h in controls. Vascular complications, emergency department (ED) visits, and readmissions were assessed over 12 months. Results: A total of 280 patients were included (mean age 70; 46.4% female; 38.9% paroxysmal AF). The VCS group had higher rates of hypertension ( Conclusion: VCS following CB-PVI is safe and feasible. No significant difference regarding acute, mid-term, and long-term groin complications was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.